Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

NICE recommends AbbVie's Aquipta (atogepant) for acute migraine with or without aura following Ph3 data
Small molecule, neurological, CGRP receptor antagonist, migraine, gepant - Read more

FDA approves Eli Lilly's EBGLYSS (lebrikizumab-lbkz) every-eight-week maintenance dosing for moderate-to-severe atopic dermatitis
Antibody, autoimmune, monoclonal antibody, atopic dermatitis, IL-13 inhibitor, lebrikizumab - Read more

Novartis, Orionis Biosciences expand molecular glue collaboration with $40M upfront, up to $1.4B milestones
Research collaboration, small molecule, molecular glue, AI/ML, milestone payments, oncology - Read more

IBA, MD Anderson Cancer Center collaborate on proton therapy health economics and cost-effectiveness evidence generation
Research collaboration, oncology, health economics, radiation therapy, data analytics - Read more

Cartesian Therapeutics, WestGene Biopharma license in vivo CAR-T platform for autoimmune diseases development
Licensing deal, autoimmune, cell therapy, mRNA, milestone payments - Read more

AmMax Bio licenses Lonza's SYNtecan ADC platform for hematological cancer treatment AMB-104, milestones and royalties eligible
Licensing deal, oncology, antibody-drug conjugate, milestone payments, royalties - Read more

Sofinnova Partners, AWS collaborate to scale AI-powered life sciences innovation through Sofia platform
Research collaboration, AI/ML, drug discovery, venture capital, digital health - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Ethyreal Bio launches with $101M to advance ETHY-001, a precision therapy targeting Graves’ disease and thyroid eye disease
Autoimmune, antibody, thyroid disease, preclinical - Read more

Parabilis Medicines raises $670M IPO, largest-ever biotech debut for cancer drug developer
Oncology, peptide therapy, platform technology, rare disease, clinical-stage - Read more

SonoThera raises $125M Series B, advancing bubble-based genetic medicine delivery platform
Gene therapy, rare disease, ultrasound delivery, Duchenne muscular dystrophy, clinical-stage - Read more

Idorsia secures up to $313M loan from Pharmakon Advisors, extending cash runway into 2028
Specialty pharma, small molecule, cardiovascular, clinical-stage - Read more

Shattuck Labs prices $75M public offering, advancing DR3 blocking antibodies for inflammatory diseases
Clinical-stage, antibody, autoimmune, bispecific - Read more

Tango Therapeutics prices upsized $600M public offering for precision cancer medicines development
Clinical-stage, oncology, precision medicine, small molecule - Read more

Summit Therapeutics plans $500M public offering to fund ivonescimab R&D and general corporate purposes
Oncology, clinical-stage, antibody - Read more

Element Biosciences raises over $175M Series E, advancing DNA sequencing and multi-omics technologies
Genomics, DNA sequencing, multi-omics, platform technology, precision medicine - Read more

Galmed Pharmaceuticals acquires Colospan for $4.5M, targeting $6B gastrointestinal diagnostics market
Medical device, gastrointestinal, major transaction, strategic - Read more

NIH appoints John Powers III as acting NIAID director amid ongoing leadership vacuum
Infectious disease, leadership, operational - Read more

Disc Medicine reaches FDA agreement to resubmit (bitopertin) via Ph3 trial for erythropoietic protoporphyria
Small molecule, rare blood disease, glycine transporter 1 inhibitor, erythropoietic protoporphyria, oral therapy - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Sanofi discontinues Ph3 MOBILIZE trial of (riliprubart) in chronic inflammatory demyelinating polyneuropathy due to insufficient efficacy
Antibody, autoimmune, complement inhibitor, chronic inflammatory demyelinating polyneuropathy, monoclonal antibody - Read more

Teva Pharmaceuticals cuts 250 jobs at TAPI unit amid prolonged search for division buyer
Active pharmaceutical ingredients, operational, cost reduction, divestiture - Read more

WuXi AppTec added to Pentagon's Chinese military companies list, triggering automatic Biosecure Act restrictions
CDMO services, biosecurity, regulatory, competitive - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here